Cart
sales@molnova.com
Home - Products - Others - Other Targets - [Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat

[Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat

CAS No. ———

[Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat( ——— )

Catalog No. M41421 CAS No. ———

[Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    [Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat
  • Note
    Research use only, not for human use.
  • Brief Description
    [Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat
  • Description
    [Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    ———
  • Formula Weight
    2402.7
  • Molecular Formula
    C98H156N34O33S2
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Codrituzumab

    Codrituzumab (GC3) is a humanized antibody against the glypican-3 hepatocellular carcinoma protein that can be used in combination with sorafenib to study incurable advanced hepatocellular carcinoma (HCC).

  • Pomalidomide-PEG2-OH

    Pomalidomide-PEG2-OH enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology.

  • Beta-Tocotrienol

    Beta-Tocotrienol to serve as a new anticancer agent for treating human lung and brain cancers. It inhibits the growth of both A549 (GI50=1.38±0.334μM) and U87MG (GI50=2.53±0.604μM) cells at rather low concentrations.

Sign In Join Free